Skip to content

Efficacy of Doxycycline Prophylaxis to Reduce Syphilis in High-Risk, HIV-Positive MSM

Doxycycline Prophylaxis or Incentive Payments to Reduce Incident Syphilis Among HIV- Infected Men Who Have Sex With Men Who Continue to Engage in High Risk Sex: A Randomized, Controlled Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02257658
Acronym
DPMSM
Enrollment
30
Registered
2014-10-06
Start date
2011-09-30
Completion date
2013-01-31
Last updated
2014-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Syphilis

Keywords

Men who have Sex with Men, HIV-positive, Syphilis, Contingency Management

Brief summary

This pilot study will investigate the feasibility of conducting a large, randomized trial comparing a structural intervention to contingency management to reduce incident syphilis infections in an especially high risk group: HIV+ men who have sex with men (MSM) who have had syphilis twice or more since their HIV diagnosis. Subjects will be randomized to receive either QD doxycycline as syphilis prophylaxis or a financial incentive to remain STI free. The investigators will : 1) measure adherence to study visits in both arms; 2) measure adherence to the prophylaxis regimen; 3) measure any changes in risk behaviors among study participants and 4) to the extent possible in a small pilot study of short duration, compare effectiveness of doxycycline with that of a monetary incentive for remaining STI free.

Interventions

BEHAVIORALIncentive
DRUGDoxycycyline

Sponsors

University of California, Los Angeles
CollaboratorOTHER
Los Angeles LGBT Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* HIV-infected MSM or transgender women who have sex with men * At least two documented and adequately treated episodes of syphilis since HIV diagnosis

Exclusion criteria

* Had a known allergy or intolerance to doxycycline * Abused alcohol or other substances which in the opinion of the investigators would jeopardize adherence to study procedures

Design outcomes

Primary

MeasureTime frame
Measure changes in the incidence of Syphilis, Gonorrhea and Chlamydia at 12 weeks, 24 weeks, 26 weeks and 48 weeks in the Doxycycline Arm and Contingency Management Arms12 Weeks, 24 Weeks, 36 Weeks and 48 Weeks

Secondary

MeasureTime frameDescription
Measure adherence to study visits in the Doxycycline and Contingency Management Arms at Weeks 12, 24, 36 and 4812 Weeks, 24 Weeks, 36 Weeks and 48 Weeks
Measure adherence to daily Doxycycline Use using Blood Samples in the Doxycycline Arm at Weeks 12, 24 and 3612 Weeks, 24 Weeks and 36 WeeksAt Weeks 12, 24 and 36, blood samples were drawn from participants in the Doxycycline arm and sent to a lab to measure doxycyline levels in each participant in the Doxycyline Arm. The purpose of this outcome is to determine if individuals in the Doxycycline Arm are consistently adhering to the daily regimen of the drug.
Measure changes in self-report sexual risk behaviors (e.g., condom use, drug use and number of partners) in the Doxycycline and Contingency Management Arms at Weeks 12, 24 and 3612 Weeks, 24 Weeks and 36 WeeksPrior to having labs drawn, participants in both the Doxycycline and Contingency Management Arms were asked about their risk behaviors in the past three months including: meth use, condom use with casual partners, condom use with regular partners, condom use with a main partner, number of casual sexual partners and number of regular sexual partners.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026